Results
There was a non-significant 26% reduction in venous thromboembolism (6% vs. 8%) in patients given fondaparinux vs. enoxaparin. The groups did not differ with regard to death and bleeding.
Although the trial did not detect a significant benefit of fondaparinux over enoxaparin it suggests that further, more powerful, trials may be required to settle the issue. Fondaparinux appears to be a safe drug.
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page